M&A Deal Summary |
|
---|---|
Date | 2009-11-03 |
Target | Schering-Plough |
Sector | Life Science |
Buyer(s) | Merck |
Deal Type | Add-on Acquisition |
Deal Value | 41.1B USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 1891 |
Sector | Life Science |
Employees | 70,000 |
Revenue | 60.1B USD (2023) |
Merck is a global healthcare company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The Company’s operations are comprised of four operating segments. These include Pharmaceutical, Animal Health, Consumer Care and Alliances. Merck's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company also has animal health operations that discover, develop, manufacture and market animal health products, including vaccines, which the Company sells to veterinarians, distributors and animal producers. Additionally, the Company has consumer care operations that develop, manufacture and market over-the-counter, foot care and sun care products. Merck was established in 1891 and is based in Rahway, New Jersey.
DEAL STATS | # |
---|---|
Overall | 8 of 35 |
Sector (Life Science) | 7 of 32 |
Type (Add-on Acquisition) | 8 of 33 |
State (New Jersey) | 2 of 3 |
Country (United States) | 7 of 27 |
Year (2009) | 1 of 1 |
Size (of disclosed) | 1 of 27 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2009-07-30 |
Merial
Duluth, Georgia, United States Merial Ltd. is an animal health company, providing a comprehensive range of products to enhance the health, well-being and performance of a wide range of animals. |
Sell | $4.0B |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2010-12-02 |
SmartCells
Beverly, Massachusetts, United States SmartCells, Inc. is focused on developing glucose-regulated SmartInsulin products for the treatment of diabetes mellitus. |
Buy | $500M |